Today: 8 November 2025
Subscribe
PACS Group (NYSE:PACS) Pops After NYSE Reprieve—Is the Nursing‑Home Giant Finally Turning the Corner? [Sep 26, 2025]
 ·  ·  ·  ·  · 

PACS Group (NYSE:PACS) Pops After NYSE Reprieve—Is the Nursing‑Home Giant Finally Turning the Corner? [Sep 26, 2025]

by
26 September 2025

Key facts (as of Sep 26, 2025)

  • Price/Move: $13.98 (+10.2% intraday); day range $12.69–$14.21; ~1.37M shares traded.
  • Today’s tape: Coverage notes shares +5% intraday during Friday’s session.  [1]
  • Latest corporate milestone: NYSE grants listing extension to Nov. 19, 2025 while PACS completes restatements and becomes current on SEC filings.  [2]
  • Operational snapshot (preliminary, 1H25): 316 facilities across 17 states; 88.9% occupancy vs. 78% industry; 64.6% of SNFs at 4–5‑star CMS QM; cash $294.2M.  [3]
  • Accounting update: PACS will restate 1H24 results—prelim. revenue overstatements of ~$15–17M (Q1) and ~$46–48M (Q2) tied to Medicare Part B recognition for certain services.  [4]
  • Governance: CFO Derick Apt resigned (Sep 2) after the audit committee found he accepted a “series of high‑value” gifts; co‑founder Mark Hancock named interim CFO (Sep 3).  [5]
  • Legal overhang: Multiple securities‑law investigations/class‑action efforts continue; Pomerantz LLP opened a fresh investigation Sep 24.  [6]
  • Street view (12‑mo targets): Average target ~$31–$35 (range $18–$50) across trackers (MarketBeat/Barron’s/Yahoo/TipRanks).  [7]

In‑depth report

What moved the stock this week

PACS rallied into the Sep 26 close with intraday gains reported by market trackers. The surge follows two mid‑September catalysts: (1) NYSE’s listing extension to Nov 19, 2025, giving the company runway to finish restatements and regain compliance; and (2) a series of governance actions, including a CFO change.  [8]

Management messaging turned incrementally constructive. CEO Jason Murray said PACS expects to report “record revenue and Adjusted EBITDA for the first six months of 2025” once filings are current. Interim Chief Compliance Officer Kathy Lauer added that PACS is “taking the right steps to best position the company” during its compliance overhaul.  [9]

Company snapshot

PACS Group is a post‑acute and senior‑living platform. As of June 30, 2025, subsidiaries operated 316 facilities with 32,208 SNF beds and 2,419 AL beds in 17 states. Occupancy was 88.9% (vs. industry ~78%), with 64.6% of SNFs scoring 4–5 stars on CMS Quality Measures—indicators management points to as proof of operating momentum. PACS also reported $294.2M cash on hand at June 30, 2025. All figures are preliminary and subject to the completion of restatements.  [10]

Where the risks came from (and what’s left to fix)

  • Revenue recognition & Medicare billing: On Jun 16, 2025, PACS said Part B respiratory and certain therapy services were incorrectly recognized as revenue in 1H24, resulting in prelim. overstatements of $15–17M (Q1) and $46–48M (Q2). The affected 2024 quarters “should no longer be relied upon,” and 10‑Q/10‑K filings for late‑2024 and 1Q25 remain outstanding.  [11]
  • Governance & leadership: On Sep 2, CFO Derick Apt resigned after the board concluded he had accepted a “series of high‑value items” from business associates—violating the code of conduct. Co‑founder Mark Hancockreturned as interim CFO on Sep 3. The board also disclosed a president‑level departure in August.  [12]
  • Listing compliance: NYSE granted another extension through Nov 19, 2025, keeping shares listed while PACS finishes restatements and becomes current with the SEC. Failure to meet that date risks delisting.  [13]
  • Litigation: Multiple law firms (e.g., Pomerantz) are investigating or have filed actions related to the restatements and disclosures; this keeps legal risk alive even if filings are completed.  [14]

What experts and primary sources are saying

  • CEO Jason Murray (Sep 11): “We expect to report record revenue and Adjusted EBITDA for the first six months of 2025 [once current on filings].”  [15]
  • Interim CCO Kathy Lauer: PACS is “taking the right steps” to enhance compliance and controls.  [16]
  • CFO.com (Sep 10) on the CFO change: the board said Apt accepted a “series of high‑value items”; Mark Hancock (co‑founder, prior CFO) was appointed interim CFO.  [17]

Street consensus, forecasts & how to read them

  • Targets: Aggregators show a $31–$35 average 12‑month target (high $50, low $18), implying >100% upside from ~$14. Sources vary on analyst counts due to coverage changes after the restatement announcement. Treat these with caution until audited financials are current.  [18]
  • Technical context: A tracker shows 50‑day SMA ~$11.36 and 200‑day SMA ~$11.08, so today’s move keeps shares above both medium‑term trend lines.  [19]

Operating pulse & industry backdrop

PACS’s preliminary metrics paint a picture of strong facility‑level performance (high occupancy, better‑than‑industry CMS quality scores) and balance‑sheet liquidity ($294.2M cash as of 6/30/25) that could support accretive acquisitions once filings normalize. That said, billing risk (Medicare Part B) and internal control enhancements remain priority workstreams through the NYSE deadline.  [20]

Timeline of recent events

  • Aug 15, 2025: President P.J. (Peter) Sanford resigns (consulting arrangement disclosed).  [21]
  • Sep 2–3, 2025: CFO Apt resigns; Hancock appointed interim CFO.  [22]
  • Sep 11, 2025: NYSE extension to Nov 19, 2025; management previews record 1H25 revenue & Adj. EBITDA; updated operating stats released.  [23]
  • Sep 24, 2025: Pomerantz begins new shareholder investigation.  [24]
  • Sep 26, 2025: Stock trades higher intraday; liquidity and trend remain in focus.  [25]

Valuation & scenarios (qualitative, given pending restatements)

  • Bull case: Restated financials filed on time; NYSE compliance restored; quality/occupancy metrics hold; Street re‑rates on cleaner earnings quality and continued tuck‑in acquisitions. Targets clustered around $31–$35 (high $50) become more credible if PACS validates record 1H25 Profitability.  [26]
  • Base case: Filings come through near deadline, but legal/oversight costs and Medicare billing guardrails compress margins; shares trade between trend and low‑end targets (e.g., $18–$31).  [27]
  • Bear case: Filing delays extend or findings worsen; NYSE compliance lapsed; litigation costs escalate; multiple compression toward single‑digit billions or delisting overhang weighs on liquidity.  [28]

What to watch next (date‑driven)

  1. Before Nov 19, 2025: Delivery of restated 1H24 financials and all delinquent 2024–1Q25/2Q25 reports to regain NYSE compliance.  [29]
  2. Management bench: Permanent CFO selection and any further board/committee changes.  [30]
  3. Legal docket: Progress in shareholder actions and any regulatory updates tied to Medicare Part B billing practices.  [31]
  4. Operating metrics: Occupancy, skilled‑mix, and acquisition cadence in 2H25; confirmation of “record” 1H25 revenue/Adj. EBITDA once filings resume.  [32]

Sources & further reading

  • Quote/metrics & NYSE extension (Sep 11): PACS IR / Business Wire press release with interim operating metrics and management quotes.  [33]
  • Restatement detail (Jun 16): PACS IR press release explaining recognition errors and preliminary overstatements.  [34]
  • CFO resignation (Sep 8 filing; Sep 10 coverage): PACS 8‑K and CFO.com/Healthcare Dive article on the code‑of‑conduct violations.  [35]
  • Share price/quote page: Yahoo Finance overview and analysis pages for PACS.  [36]
  • Analyst targets/consensus: MarketBeat forecast page; Barron’s research snapshot; TipRanks consensus.  [37]
  • Today’s trading color: MarketBeat intraday note.  [38]
  • Additional background: Reuters coverage of the 2024 IPO.  [39]

Quick take

PACS looks fundamentally busy and operationally resilient, but the investment case hinges on execution between now and Nov 19: finish the restatements, restore timely reporting, and steady governance. If PACS clears those hurdles, Street targets suggest ample upside; if not, listing and litigation risk remain the swing factors.

This report is for information only and not investment advice.

References

1. www.marketbeat.com, 2. www.businesswire.com, 3. www.businesswire.com, 4. ir.pacs.com, 5. ir.pacs.com, 6. www.globenewswire.com, 7. www.marketbeat.com, 8. www.marketbeat.com, 9. www.businesswire.com, 10. www.businesswire.com, 11. ir.pacs.com, 12. ir.pacs.com, 13. www.businesswire.com, 14. www.globenewswire.com, 15. www.businesswire.com, 16. www.businesswire.com, 17. www.cfo.com, 18. www.marketbeat.com, 19. www.marketbeat.com, 20. www.businesswire.com, 21. ir.pacs.com, 22. ir.pacs.com, 23. www.businesswire.com, 24. www.globenewswire.com, 25. www.marketbeat.com, 26. www.businesswire.com, 27. www.marketbeat.com, 28. www.businesswire.com, 29. www.businesswire.com, 30. ir.pacs.com, 31. www.globenewswire.com, 32. www.businesswire.com, 33. www.businesswire.com, 34. ir.pacs.com, 35. ir.pacs.com, 36. finance.yahoo.com, 37. www.marketbeat.com, 38. www.marketbeat.com, 39. www.reuters.com

Tags:

Marcin Frąckiewicz Latest posts

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

  1. Nasdaq Posts Worst Week Since April as AI Selloff Deepens; Mixed Close on Nov. 7 After Tech-Led Rout Nov. 6, Jobs Data Blackout Weighs on Sentiment
  2. Stock Market Today 08.11.2025
  3. Microsoft Stock Today (MSFT): Eight‑Day Slide Hits Longest Streak Since 2011 — Close, Catalysts, and What’s Next (Nov 7, 2025)
  4. Tesla Stock Today (Nov 7, 2025): TSLA Slides After Shareholders Approve Elon Musk’s $1 Trillion Pay Package

Stock Market Today

  • GM Fair Value Update: DCF Signals GM Near Intrinsic Value
    November 8, 2025, 6:44 AM EST. Using a 2-stage Free Cash Flow to Equity model, the analysis puts GM's fair value at around US$85.19 per share, versus a current price near US$70.75 and an analyst target of US$73.15. The result suggests GM trades close to its intrinsic value. The model derives a PVCF of US$47 billion and applies a 13% discount rate, with a terminal value calculated via the Gordon Growth method at a 3.3% perpetuity growth. The takeaway: even with modest growth assumptions, the stock could be fairly valued today; bulls note the upside if growth rates stabilize, while bears stress sensitivity to long-term cash flows and discount rate assumptions.
  • Nvidia Could Hit a $15 Trillion Market Cap by 2030 on AI Infrastructure Boom
    November 8, 2025, 6:42 AM EST. Nvidia dominates GPUs for the AI era, with CEO Jensen Huang citing a wave of data-center spend. The company has hundreds of billions in unfilled orders and a projected surge in AI infrastructure capex toward $3-4 trillion by 2030. If Nvidia sustains roughly current market share, analysts see potential revenue around $1 trillion by 2030 and net income near $500 billion, assuming margins stay above 50%. A 30x earnings multiple implies a $15 trillion market cap, versus about $5 trillion today. The bullish thesis hinges on demand remaining robust, supply catching up, and shares outstanding not expanding dilutively. Investors should weigh this as a long-duration AI play with substantial upside but significant execution and valuation risks.
  • Arcos Dorados Valuation in Focus After Recent Price Move (NYSE:ARCO)
    November 8, 2025, 6:26 AM EST. Arcos Dorados Holdings (NYSE:ARCO) has seen mixed momentum after a recent price move. Over the last month the stock rose about 3%, while three-year gains hover near 7%. The stock trades around $7.06, leaving a mixed picture on a one-year total-return basis as longer-term growth looks encouraging. The current narrative flags undervalued, with a fair value around $10.4 and a potential upside, driven by digital adoption, loyalty programs, app engagement, and higher identified sales. However, a rival SWS DCF view suggests fair value near $2.14, underscoring a wide valuation split. Investors should weigh macro volatility, competitive pressure, and margin effects against upside from digital channels and international expansion.
  • International IPO Weekly Winners & Losers: HK Debuts Amid Market Selloff
    November 8, 2025, 6:03 AM EST. Last week, the International IPO Index fell -2.4% while the ACWX ex-US ETF slipped -0.6%, signaling softness in global listings. The standout winner was Kioxia in Japan up +11.2%, with Laopu Gold in Hong Kong at the bottom, down -10.9%. Hong Kong hosted a flurry of sizable debuts, many trading above issue despite broader weakness, and the pipeline remains robust. Nearly a dozen sizable listings hit the market, including four Hong Kong cross-listings posting double-digit declines: Seres (-13%), Pony AI (-20%), Joyson Electronic (-16%), plus others in Manila, Johannesburg, and Hong Kong. The Week Ahead features three Indian IPOs: Lenskart, Groww, and Pine Labs, plus Softcare in Africa and more from India and HK. The index finished -2.4% on the week, vs -0.6% for the ex-US benchmark.
  • DRDGOLD Valuation Spotlight: Is DRD Undervalued Ahead of 200k oz Target and 18-Year Dividend Streak?
    November 8, 2025, 6:00 AM EST. DRDGOLD (NYSE: DRD) is attracting attention as it targets 200,000 ounces of annual gold output from tailings by 2029, supported by an 18-year dividend streak and a debt-free expansion plan. The stock has surged ~190% YTD and ~139% over the last year, underpinned by strong retreatment operations and a hopeful long-term outlook. The shares trade at a P/E of 17.4x, below Metals & Mining peers, hinting at potential undervaluation. A DCF analysis shows a larger gap: at $26.14 the stock trades roughly 45.6% below our fair value of $48.06. Upside hinges on gold price stability and execution. Risks include commodity volatility and operational setbacks. Is the rally already pricing in growth, or could further upside emerge?
Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update
Previous Story

Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update

Iran’s Rial Crisis Deepens: USD Soars Past 1.08 Million on Black Market Amid Sanctions Fears (قیمت دلار)
Next Story

Iran’s Rial Crisis Deepens: USD Soars Past 1.08 Million on Black Market Amid Sanctions Fears (قیمت دلار)

Related Articles

Go toTop